The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES.

La larga maratón de los DES ultrafinos vs struts finos de 2ª generación

The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs or polymers, the real evolution seems to lie on strut thickness.

Contemporary 2nd generation DES are considered the standard of care for coronary angioplasty. A previous meta-analysis of 10 randomized studies with over 11,000 patients showed the advantage of ultrathin DES, but with only with a 1-year follow-up (a very short time to consider the dawn of a new generation).

This new meta-analysis published in the European Heart Journal compared randomized studies with ultrathin DES (<70 microns thick) vs. the classic 2nd generation device.

The pre-specified primary endpoint was target lesion failure, a composite of cardiac death, infarction, or clinically justified target lesion revascularization. Secondary endpoints included stent thrombosis and all-cause mortality.

Sixteen randomized studies with over 20,000 patients and 2.5 years of follow-up were eligible.


Read also: Best Revascularization Strategy in Patients with Left Ventricular Deterioration.


Ultrathin-strut DES were associated with a 15% reduction in long-term target vessel failure compared to “conventional” 2nd generation DES (risk ratio [RR]: 0.85; 95% confidence interval [CI]: 0.76 to 0.96; p = 0.008), led by a 25% reduction in clinically justified revascularization (RR: 0.75; 95% CI: 0.62 to 0.92; p = 0.005).

No differences were observed between the two devices in terms of infarction, stent thrombosis, cardiac death, or all-cause mortality.

Conclusion

At a mean follow-up of 2.5 years, ultrathin-strut stents reduced target vessel failure mainly due to a significant reduction in revascularizations compared with “classical” 2nd generation DES.

ehab280

Original Title: Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.

Reference: Mahesh V. Madhavan et al. European Heart Journal (2021) 42, 2643–2654 doi:10.1093/eurheartj/ehab280.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....